Related Experiment Video

Updated: Jun 8, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

EGFR and KRAS in colorectal cancer

Ben Markman1, Francisco Javier Ramos, Jaume Capdevila

  • 1Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.

Advances in Clinical Chemistry
|September 23, 2010
PubMed

Insights

Testing for KRAS mutations is crucial for colorectal cancer (CRC) patients receiving epidermal growth factor receptor (EGFR) targeted therapies. Wild-type KRAS status ensures treatment efficacy and minimizes unnecessary toxicity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Epidermal growth factor receptor (EGFR) is a key target in metastatic colorectal cancer (CRC) treatment.
  • Monoclonal antibodies (mAbs) targeting EGFR are a standard therapy.
  • KRAS mutations predict resistance to EGFR-targeted mAbs.

Purpose of the Study:

  • To highlight the importance of KRAS mutation testing in CRC patients.
  • To emphasize the role of KRAS status in guiding EGFR-targeted therapy decisions.
  • To explore potential new therapeutic targets within EGFR signaling pathways.

Main Methods:

  • Review of current clinical guidelines and therapeutic strategies for metastatic CRC.
  • Analysis of the role of KRAS as an EGFR signaling effector.
  • Discussion of the clinical implications of KRAS mutation testing.

Main Results:

  • KRAS mutation status is a strong predictor of resistance to EGFR-targeted mAbs in CRC.
  • Routine KRAS mutation testing is recommended for all CRC patients considered for EGFR-targeted therapy.
  • Wild-type (WT) KRAS status identifies patients likely to benefit from EGFR-targeted mAbs.

Conclusions:

  • KRAS mutation testing is essential for optimizing treatment selection in metastatic CRC.
  • Identifying WT KRAS status improves patient outcomes and reduces healthcare costs.
  • Further investigation into other EGFR pathway components may reveal additional therapeutic targets.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...